Etid klinik pou BPCO nan Houston, TX
15 etid pou BPCO ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Ap rekriteFaz 2
- Baylor College of Medicine Medical Center, Houston
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Ap rekriteFaz 3
- Trio Clinical Trials- Site Number : 8400106, Houston
- HDH Research- Site Number : 8400104, Houston
- Baylor College of Medicine- Site Number : 8400076, Houston
- ak 2 plis
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Ap rekriteFaz 3
- SE Houston- Site Number : 8400120, Houston
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 2
- Research Site, Houston
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Ap rekriteFaz 2
- Baylor College of Medicine, Houston
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Ap rekriteFaz 3
- Research Site, Houston
- Research Site, Houston
- Research Site, Humble · 17 mi lwen
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Ap rekriteFaz 3
- Research Site, Houston
- Research Site, Houston
- Research Site, Houston
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 2/3
- Greater Heights & Memorial Pulmonary and Sleep, Houston
- Houston Pulmonary Sleep and Allergy Associates, Houston
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Ap rekriteFaz 3
- Research Site, Houston
- Research Site, Houston
- Research Site, Houston
STRIVE Post-Market Registry Study
Ap rekriteEtid obsèvasyon
- University of Texas Health Science Center at Houston, Houston
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Ap rekriteFaz 3
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Ap rekrite
- Houston Methodist/Primary Critical Care, Houston
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Ap rekriteFaz 3
- GSK Investigational Site, Houston
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Ap rekriteEtid obsèvasyon
- Horizon Clinical Research Group, Houston
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Ap rekrite
- Respire Research Institute, Houston
Etid BPCO nan lòt vil
- Philadelphia, PA22 etid
- Miami, FL18 etid
- Birmingham, AL17 etid
- Boston, MA17 etid
- Orlando, FL15 etid
- Chicago, IL14 etid
- Baltimore, MD13 etid
- Dallas, TX12 etid
- Pittsburgh, PA12 etid
- New York City, NY11 etid
- Winston-Salem, NC9 etid
- Charlotte, NC9 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)122 etid
- Kansè Metastatik104 etid
- Kansè kolorektal103 etid
- Kansè ovè90 etid
- Leksemi mieloïd egi86 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt69 etid
- Kansè pankreyas62 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.